Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

News Daily News

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

Todd Neale

December 16, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

News Daily News

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

L.A. McKeown

February 23, 2024

News Daily News

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

L.A. McKeown

August 31, 2023

News Daily News

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Michael O'Riordan

June 23, 2023

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

L.A. McKeown

January 13, 2023

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

Michael O'Riordan

March 01, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

Uptick in ‘Implausible’ Cancers Reported After ARB Recalls

L.A. McKeown

August 20, 2021

News Daily News

Making the Case for Sex-Specific CVD Guidelines

L.A. McKeown

July 08, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Daily News

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

L.A. McKeown

June 08, 2020

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

L.A. McKeown

October 23, 2019

News Daily News

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Michael O'Riordan

October 18, 2019

News Daily News

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Marcus A. Banks

July 12, 2019

Advertisement

Aprocitentan Effective in CKD Patients With Resistant Hypertension: PRECISION

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

CMS Announces Negotiated Medicare Prices for First 10 Drugs

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Efforts to Up PCSK9 Use Still Falling Short, Analysis Finds

First Drugs Chosen for Medicare Negotiations Hit Close to Home for Cardiologists

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Skipping Low-Value Cardiovascular Care Could Save Billions: AHA

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Uptick in ‘Implausible’ Cancers Reported After ARB Recalls

Making the Case for Sex-Specific CVD Guidelines

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content